fasudil (AT 877)

Subscribe to Selected New Research on fasudil

131 relevant articles (28 outcomes, 28 trials/studies) found for this Bio-Agent

Description: intracellular calcium antagonist; structure in first source

Also Known As:

AT 877; 1-(5-isoquinolinesulfonyl)homopiperazine; AT-877; AT877; HA 1077; HA-1077; fasudil hydrochloride; 1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Sulfur Compounds: 82

Sulfones: 120

Sulfonamides: 749

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: 204

fasudil: 131

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Piperazines: 17

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: 204

fasudil: 131

2-Ring Heterocyclic Compounds

Isoquinolines: 17

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: 204

fasudil: 131

Experts

1.	Shimokawa, Hiroaki: 7 articles (02/2007 - 04/2002)
2.	Satoh, Shin-ichi: 4 articles (06/2008 - 11/2002)
3.	Shibuya, Masato: 3 articles (06/2008 - 11/2005)
4.	Fukumoto, Yoshihiro: 3 articles (02/2007 - 09/2004)
5.	Takeshita, Akira: 3 articles (10/2004 - 04/2002)
6.	Takanashi, Y: 3 articles (11/2001 - 03/2001)
7.	Ishida, T: 3 articles (11/2001 - 03/2001)
8.	Seto, Minoru: 2 articles (06/2008 - 11/2005)
9.	Takakura, Kintomo: 2 articles (06/2008 - 08/2007)
10.	Suzuki, Yoshio: 2 articles (06/2008 - 08/2007)

Related Diseases

1.	Pulmonary Hypertension (Ayerza Syndrome) 02/20/2004 - "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction" 01/01/2007 - "The aim of this study was to explore whether RhoA/Rho-kinase pathway is involved in the pathogenesis of high flow induced pulmonary hypertension and whether long-term inhibition of RhoA/Rho-kinase pathway with fasudil could attenuate high flow induced pulmonary artery remodeling in rats" 01/05/2007 - "Fasudil treatment could improve pulmonary hypertension by inhibiting Rho kinase activity." 12/01/2006 - "Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension]" 03/01/2005 - "Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension." Order ALL the reference details at left...
2.	Stroke (Strokes) 11/15/2005 - "CONCLUSION: Treatment with fasudil within 48 h of acute ischemic stroke onset significantly improved the patient's clinical outcome" 09/01/2000 - "Fasudil may be beneficial in the treatment of acute ischemic stroke." 01/12/2007 - "The present findings indicate that the RKI fasudil reduces ischemic neuronal damage with a wide therapeutic time window in gerbil, and may be useful in the treatment of acute ischemic stroke in humans." 11/15/2005 - "Further evaluations, for example, 3-month functional outcomes in a larger clinical trial, may help to define the efficacy of fasudil in acute ischemic stroke." 11/15/2005 - "This study found fasudil to be a useful and safe drug for patients with acute ischemic stroke" Order ALL the reference details at left...
3.	Spasm (Spasms) 09/01/2004 - "In this study, we examined the inhibitory effect of fasudil in patients with intractable severe coronary spasm after CABG" 03/01/2008 - "These findings support and extend the previous results that showed the feasibility of employing fasudil as a novel therapeutic approach for coronary spasm." 03/01/2008 - "CONCLUSIONS: Fasudil further dilated the site of coronary spasm, which had already been treated with NTG in patients with vasospastic angina" 09/01/2004 - "In conclusion, the treatment with fasudil may be useful to treat intractable and otherwise fatal coronary spasm resistant to intensive conventional vasodilator therapy after CABG." 09/01/2004 - "Fasudil successfully resolved the spasm and improved myocardial ischemia in all patients without any systemic adverse effects" Order ALL the reference details at left...
4.	Myocardial Ischemia (Ischemic Heart Diseases) 11/15/2005 - "BACKGROUND: Several small, non-placebo-controlled trials suggest that fasudil reduces myocardial ischemia in patients with stable or vasospastic angina" 01/01/2003 - "In contrast, 11 of the 13 patients pretreated with fasudil had no evidence of myocardial ischemia during the second infusion of ACh (p < 0.01)" 09/01/2004 - "Fasudil successfully resolved the spasm and improved myocardial ischemia in all patients without any systemic adverse effects" 01/01/2005 - "Emerging clinical data have shown that oral fasudil 80 mg three times daily is effective in preventing myocardial ischemia in patients with stable angina pectoris" 04/02/2002 - "CONCLUSIONS: Fasudil was effective in preventing ACh-induced coronary artery spasm and resultant myocardial ischemia in patients with vasospastic angina" Order ALL the reference details at left...
5.	Right Ventricular Hypertrophy 02/20/2004 - "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction" 12/01/2006 - "Long-term blockade of Rho-kinase with fasudil (100 mg/kg/d) for 3 weeks markedly improved PH and right ventricular hypertrophy in WT mice with a lesser but significant inhibition noted in eNOS mice" 01/05/2007 - "Fasudil treatment lowered pulmonary artery systolic pressure, suppressed pulmonary artery smooth muscle cells proliferation, attenuated pulmonary artery medial wall thickening and inhibited right ventricular hypertrophy together with significant suppression of Rho kinase activity but not Rho activity" 01/01/2007 - "Compared with the control groups, exposure to high blood flow induced a significant elevation of right ventricle systolic pressure at week 8, significant increase of the mean percentage of media wall thickness (%MT) in moderate size pulmonary arteries both at weeks 4 and 8, marked elevation of right ventricle (RV) to left ventricle plus septum (LV+SP) weight ratio at week 8, significant increase of PCNA-positive SMCs percentage at week 4 and significant decrease of TUNEL-positive SMCs percentage both at weeks 4 and 8. High pulmonary blood flow also induced 3.19+/-0.28-fold increase of RhoA and 3.63+/-0.52-fold increase of Rho-kinase over the control group at week 4, 1.57+/-0.35-fold increase of RhoA and 2.36+/-0.39-fold increase of Rho-kinase over the control group at week 8. Compared with the shunt groups, fasudil treatment significantly suppressed Rho-kinase activity at both weeks 4 and 8, improved pulmonary hypertension at week 8, attenuated right ventricular hypertrophy at week 8, and enhanced pulmonary vascular remodeling both at weeks 4 and 8, which were associated with suppressed pulmonary artery smooth muscle cells proliferation at week 4 and apoptosis both at weeks 4 and 8. These results indicated that RhoA/Rho-kinase mediated pathway participated in the process of high flow induced pulmonary artery remodeling; inhibition of Rho kinase with fasudil could attenuate pulmonary artery remodeling." Order ALL the reference details at left...

Related Drugs and Biologics

1.	rho-Associated Kinases
2.	Messenger RNA (mRNA)
3.	hydroxyfasudil
4.	Atrial Natriuretic Factor (ANF)
5.	Creatinine
6.	Collagen
7.	Y 27632
8.	Calcium
9.	ozagrel
10.	Monocrotaline

Related Therapies and Procedures

1.	Sutures (Suture)
2.	Nephrectomy
3.	Induced Hypothermia
4.	Homologous Transplantation (Allograft)
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)

Best Treatments:
Research Summary Report
on Pulmonary Hypertension

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 553 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>